Clinical experience gained from the use of 120 steatotic donor livers for orthotopic liver transplantation

Liver Transplantation

Volumn 9, Issue 5, 2003, Pages 500-505

  Verran, Deborah J ^a   Kusyk, Taras ^a   Painter, Dorothy ^a   Fisher, Jodi ^a   Koorey, David ^a   Strasser, Simone ^a   Stewart, Graham ^a   McCaughan, Geoffery ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTAGLANDIN E1;

ACUTE GRAFT REJECTION; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BRAIN HEMORRHAGE; CADAVER DONOR; CAUSE OF DEATH; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; RECIPIENT; STEATOSIS;

EID: 0038104953     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2003.50099     Document Type: Article

References (23)

1. Trevisani F, Colantoni A, Caraceni P, Van Thiel DH. The Use of donor fatty liver for liver transplantation: a challenge or a quagmire? J Hepatol 1996;24:114-121.
2. Adam R, Reynes M, Johann M, Morino I, Astarcioglu I, Kafetzis I, et al. The outcome of steatotic grafts in liver transplantation. Transplant Proc 1991;23:1538-1540.
3. Selzner M, Clavien PA. Fatty liver in liver transplantation and surgery. Semin Liver Dis 2001;21:105-113.
4. Urena MAG, Gonzalez EM, Romero CJ, Ruiz-Delgado FC, Sanz CM. An approach to the rational use of steatotic donor livers in liver transplantation. Hepatogastroenterology 1999;46: 1164-1178.
5. Urena MAG, Ruiz-Delgado FC, Gonzalez EM, Segurola CL, Romero CJ, Garcia IG, et al. Assessing risk of the use of livers with macro and microsteatosis in a liver transplant program. Transplant Proc 1998;30:3288-3291.
6. Urena MAG, Ruiz-Delgado FC, Gonzalez EM, Romero CJ, Garcia IG, Segurola CL, et al. Hepatic steatosis in liver transplant donors: Common feature of donor population? World J Surg 1998;22:837-844.
7. Chui AKK, Haghighi K, Painter D, Jayasundera M, Hall G, Rao ARN, et al. Donor fatty (steatotic) liver allografts in orthotopic liver transplantation. Transplant Proc 1998;30:3286-3287.
8. Chui AKK, Shi LW, Rao ARN, Verran DJ, Painter D, Koorey D, et al. Donor Fatty (steatotic) liver allografts in orthotopic liver transplantation: A revisit. Transplant Proc 2000;32:2102-2102.
9. Verran DJ, Gurkan A, Dilworth P, Painter D, Chui A, Dorney S, et al. Inferior Liver allograft survival from cadaveric donors > 50 years of age? Clin Transplant 2001;15:106-110.
10. Isai H, Sheil AGR, McCaughan G, Dolan P, Waugh R. Successful reversal of primary graft nonfunction in a liver transplant patient treated with prostaglandin E1 Aust N Z J Surg 1992;62: 314-316.
11. D'Alessandro AM, Kalayoglu M, Sollinger H, Hoffman R, Reed A, Knechtle S, et al. The predictive value of liver biopsies for the development of primary nonfunction after orthotopic liver transplantation. Transplantation 1991;51:157-163.
12. Ploeg RJ, D'Alessandro AM, Knechtle SJ, Stegall MD, Pirsch JD, Hoffman RM, et al. Risk factor for primary dysfunction after liver transplantation-a multivariate analysis. Transplantation 1993;55:807-813.
13. Canelo R, Braun F, Sattler B, Klinge B, Lorf Th, Ramadori G, et al. Is a fatty liver dangerous for transplantation? Transplant Proc 1999;31:414-415.
14. Fishbein TM, Fiel MI, Emre S, Cubukcu O, Guy SR, Schwartz ME, et al. Use of liver with microvesicular fat safely expands the donor pool. Transplantation 1997;64:248-251.
15. Mor E, Klintman GB, Gonwa TA, Solomon H, Holman MJ, Gibbs JF, et al. The use of marginal donors for liver transplantation. Transplantation 1992;52:383-386.
16. Zamboni F, Franchello A, David E, Rocca G, Ricchiuti A, Lavezzo B, et al. Effect of macrovesicular steatosis and other donor and recipient characteristics on the outcome of liver transplantation. Clin Transplant 2001;15:53-57.
17. Todo S, Demetris AJ, Makowka L, Taperman L, Podesta L, Shaver T, et al. Primary nonfunction of hepatic allografts with preexisting fatty infiltration. Transplantation 1989;47:903-905.
18. Strasberg SM, Howard TK, Molmenti EP, Hertl M. Selecting the donor liver: Risk factors for poor function after orthotopic liver transplantation. Hepatology 1994;20:829-838.
19. Husberg B, Genyk Y, Klintmalm GB. A new rat model for studies of the ischemic injury after transplantation of fatty livers: improvement after postoperative administration of prostaglandin. Transplantation 1994;57:457-482.
20. Greig PD, Woolf GM, Sinclair SB, Abecassis M, Strasberg SM, Taylor BR, et al. Treatment of Primary Liver Graft Nonfunction with Prostaglandin E1. Transplantation 1989; 48:447-453.
21. Giostra E, Chen H, Deng H, Buhler L, Romand JA, Hadengue A, et al. Prophylactic administration of prostaglandin e1 in liver transplantation: Results of a pilot trial. Transplant Proc 1997; 29:2381-2384.
22. Klein AS, Cofer JB, Pruett TL, Thuluvath PJ, McGory R, Uber L, et al. Prostaglandin e1 administration following orthotopic liver transplantation: A randomized prospective multicenter trial. Gastroenterology 1996;111:710-715.
23. Berengeuer M, Prieto M, San Juan F, Rayon JM, Martinez F, Carrasco D, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002;36:202-210.